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Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmaco-
logical therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-
transporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reduc-
tions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal mus-
cle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the 
effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated 
with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over 
half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent 
with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, 
the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies 
to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.
Keywords: Glucagon-like peptide-1 receptor agonists; Sodium-glucose cotransporter 2 inhibitors; Diabetes mellitus, type 2; Weight 
loss; Body composition; Lean body mass
INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and so-
dium-glucose cotransporter 2 inhibitors (SGLT2is) are novel 
glucose-lowering therapies that are prominent in the most recent 
guidelines for the management of hyperglycaemia in type 2 dia-
betes mellitus (T2DM) and recommended as preferred second-
line pharmacological therapies after metformin, alongside on-
going lifestyle management (predominantly diet and physical 
activity) [1]. They are particularly recommended when, in addi-
tion to glucose lowering, there is a compelling need to reduce 
body weight (BW) [1].
Received: 3 September 2019, Revised: 10 September 2019, 
Accepted: 17 September 2019
Corresponding author: Melanie Jane Davies
Diabetes Research Centre, Leicester General Hospital, Gwendolen Rd, Leicester, 
LE5 4PW, UK
Tel: +44-116-258-6481, E-mail: melanie.davies@uhl-tr.nhs.uk
*These authors contributed equally to this work.  
Copyright © 2019 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribu-
tion, and reproduction in any medium, provided the original work is properly 
cited.
Endocrinol Metab 2019;34:247-262
https://doi.org/10.3803/EnM.2019.34.3.247
pISSN 2093-596X  ·  eISSN 2093-5978
Sargeant JA, et al.
248 www.e-enm.org Copyright © 2019 Korean Endocrine Society
In large cardiovascular outcome trials, several GLP-1RAs (li-
raglutide, semaglutide, exenatide once-weekly, albiglutide and 
dulaglutide) have shown compelling cardiovascular protection in 
the form of reduced risk of major adverse cardiovascular events, 
along with some renal benefits [2,3]. A number of SGLT2is 
(canagliflozin, dapagliflozin, and empagliflozin) have also 
shown cardiovascular benefits and greater renal protection, in ad-
dition to reduced hospitalization for heart failure [4-6]. Both 
classes of therapy also elicit clinically relevant weight loss [1], 
with liraglutide gaining an independent license (at a higher dose 
of 3 mg) for use in obesity management. Importantly, the glu-
cose-dependent mechanisms of action of both therapies mean 
that their beneficial effects come with low risk of hypoglycaemia, 
particularly when not used with sulphonylureas or insulin [1].
The dual effects of weight loss and improved glycaemic con-
trol associated with GLP-1RAs and SGLT2is are appealing. 
Obesity and T2DM are intrinsically linked, and each are associ-
ated with increased risk of multiple comorbidities [7]. Notably, 
however, previous studies demonstrate that when BW is re-
duced through dietary energy restriction, not all of the resulting 
weight loss can be attributed to fat mass (FM), with approxi-
mately 25% to 33% estimated to comprise of reductions in lean 
body mass (LBM) [8,9]. This is important because LBM (pre-
dominantly comprised of skeletal muscle) has several important 
functions. It acts as a primary site of glucose disposal (with 
lower skeletal muscle mass contributing to poorer glycaemic 
control [10]), and is a strong determinant of resting metabolic 
rate; and thus loss of skeletal muscle with weight loss may pre-
dispose individuals to a greater chance of weight regain [11]. 
Lower muscle mass and function, associated with impaired 
muscular strength and endurance, also result in a higher risk of 
falls, hospitalisation and physical frailty [12,13]. The important 
association between T2DM and frailty is becoming increasingly 
recognised [14], with frailty up to five times more likely in indi-
viduals with T2DM compared to those without [14-17]. T2DM 
represents a state of accelerated metabolic ageing, and some of 
this frailty risk may be underpinned by an increased loss of 
LBM and function [18-20]. 
Consequently, whilst weight loss is an important goal in the 
management of several obesity-associated comorbidities, in-
cluding T2DM, and pharmacological therapies that support 
such weight loss are appealing, it is important to understand the 
impact of these therapies on body composition. The aim of this 
narrative review is to describe the effects of GLP-1RAs and 
SGLT2is upon body composition, with a particular focus on 
LBM and skeletal muscle.
DEFINITIONS AND MEASUREMENT OF 
BODY COMPOSITION
To interpret changes in body composition, it is important to un-
derstand the basic theory and appreciate the advantages and dis-
advantages of different measurement methods. 
Broadly, body composition measurement divides the body 
into “compartments” on the basis of differing physical proper-
ties, which commonly include FM, fat free mass (FFM), LBM, 
skeletal muscle mass, bone mineral content and total body water 
(TBW). Definitions of these terms are provided in Table 1. 
Direct methods of body composition include computed to-
mography (CT) and magnetic resonance imaging (MRI) [21]. 
Whilst these techniques have the highest accuracy, they are also 
expensive, and not widely used in clinical practice. More com-
mon measures, which estimate body composition indirectly, in-
clude bioelectrical impedance analysis (BIA), air displacement 
plethysmography (ADP) and dual-energy X-ray absorptiometry 
(DXA). 
BIA uses a small alternating current to measure body imped-
ance. Estimates of body composition are provided through in-
built equations based on assumed impedance of different bio-
logical tissues [22]. BIA is quick, easy and relatively inexpen-
sive, but less precise than other available methods and influ-
enced by factors such as hydration status.
ADP provides an estimate of body composition by combining 
body volume, measured using the displacement of air within a 
Table 1. Definitions of Body Composition Compartments
Fat mass Mass of all adipose tissue 
Fat free mass Fat free mass is total body mass minus total fat mass
Lean body mass Lean body mass is fat free mass minus total bone mass
Skeletal muscle mass Skeletal muscle mass is lean body mass minus connective tissue, skin, and other organs
Total body water The summation of intra- and extra-cellular water
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sealed measurement chamber, with BW to calculate body densi-
ty. Body density is then used to estimate body composition us-
ing pre-defined formulae [23]. ADP is relatively quick to per-
form and non-invasive, but requires operation by trained per-
sonnel to avoid undue error.
DXA remains a prominent and preferred technique in clinical 
trials, balancing a high level of accuracy with comparatively 
lower costs than MRI and CT. DXA provides whole-body and 
regional estimates of FM, FFM, LBM, and bone mineral con-
tent [21]; using a small safe dose of radiation. It is relatively 
quick and provides much greater accuracy than BIA.
METHODS
We searched for published studies reporting data on the effects 
of GLP-1RAs and SGLT2is on body composition using the on-
line database, PubMed, from inception to August 2019, using 
search terms related to GLP-1RAs, SGLT2is, weight loss and 
body composition. We included studies using DXA, BIA, ADP, 
MRI, or CT to measure body composition in any human study 
population before and after 2 or more weeks of GLP-1RA and/
or SGLT2i therapy. Where appropriate, the following assump-
tions were used during data extraction:
(1) Where data were reported for mean total BW and mean 
body fat percentage, we estimated mean FM as; BW divided by 
100, multiplied by body fat percentage.
(2) Where mean BW and mean FM were available (including 
when FM was estimated as above) we estimated FFM as; BW 
minus FM.
We used FFM to cautiously infer changes in LBM, with rec-
ognition of their subtle differences as outlined in Table 1. Due to 
variation in techniques used and methods of reporting, we did 
not sum different body compartments to estimate total LBM, 
FFM or BW change.
RESULTS
Details of all eligible studies identified in our search can be 
found in Tables 2-4 [24-68]. The following paragraphs provide 
an overview of the findings for each individual therapy within 
both drug classes. For ease of reading, medication doses are not 
included in text unless providing specific context or compari-
son. Figs. 1, 2 present the relative proportion of weight loss that 
could be attributed to FM and LBM/FFM with GLP-1RA and 
SGLT2i therapy, respectively. Our literature search yielded no 
data for lixisenatide, albiglutide, or ertugliflozin. 
Glucagon-like peptide-1 receptor agonists
We identified 17 studies (two within a single manuscript) re-
porting changes in body composition with liraglutide (n=10), 
exenatide (n=5), semaglutide (n=1), or dulaglutide (n=1). 
Thirteen of these studies used DXA to measure body composi-
tion, two used BIA alone, one used a combination of BIA and 
CT, and one used ADP. 
Liraglutide
Four manuscripts, containing data from five studies, reported 
relative contributions of LBM/FFM to total weight loss with li-
raglutide therapy, ranging from 30% to 47% [26,28,29,32]. This 
included data from separate sub-studies contained within two 
phase 3 trials in the Liraglutide Effect and Action in Diabetes 
(LEAD) programme. In LEAD 2, there was a step-wise increase 
in the magnitude of both total weight loss (0.9, 2.0, and 3.2 kg) 
and the relative contribution of LBM (33%, 40%, and 47%) 
when liraglutide was prescribed at 0.6, 1.2, and 1.8 mg once-
daily for 26 weeks [28]. In LEAD 3, 1.2 mg liraglutide elicited 
2.4 kg weight loss after 52 weeks, with 46% comprising LBM. 
Liraglutide 1.8 mg resulted in a similar magnitude of weight 
loss at 52 weeks (2.3 kg) but the relative contribution of LBM 
was considerably higher (65.2%). Two further trials using DXA 
report similar results in individuals with obesity and T2DM 
(30% of 5.0 kg weight loss over 12 weeks) [29] and polycystic 
ovarian syndrome (PCOS; 46% of 5.2 kg weight loss over 26 
weeks) [26]. Furthermore, a single study, using BIA, reported 
5.6 kg weight loss after 24 weeks of liraglutide therapy in indi-
viduals with type 1 diabetes mellitus, of which 41% constituted 
LBM [32].
Conversely, two studies report a comparatively smaller con-
tribution of LBM/FFM to total weight loss with 24 weeks lira-
glutide treatment in overweight/obese individuals with T2DM 
(16% of 2.5 kg weight loss with 3 mg once-daily), and those 
with T2DM and non-alcoholic fatty liver disease (NAFLD) (4% 
of 5.6 kg weight loss) [25,31]. Furthermore, two studies report 
no change or marginal increases in LBM after 24 and 8 weeks 
of treatment, respectively [27,30]. The final manuscript identi-
fied reductions in LBM in individuals undergoing liraglutide 
therapy at 1.2, 1.8, 2.4, and 3.0 mg for 20 weeks, but did not re-
port total BW change for the subset of individuals undergoing 
body composition assessment [24].
Exenatide
We identified five studies examining the impact of exenatide on 
body composition, reporting similar, although more heteroge-
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neous, findings than those for liraglutide. Two studies used 
DXA to assess changes in body composition with 14 weeks of 
exenatide treatment in individuals with obesity with or without 
schizophrenia. These studies reported a mean weight loss of 2.0 
and 2.3 kg, respectively, of which the relative contribution of 
FFM to total weight loss was 40% and 52% [33,35]. 
A separate study reported 3.5 kg weight loss after 16 weeks of 
treatment in individuals with overweight/obesity and T2DM 
and reported that 11.4% of weight loss comprised of LBM [36]. 
One further study reported a small increase (0.3 kg) in LBM af-
ter 52 weeks of treatment in individuals with T2DM [34]. The 
final study identified (utilising BIA to assess changes in body 
composition over 12 weeks in individuals with obesity and 
T2DM), did not report changes in LBM, but reported a loss of 
FM that was greater than the total weight loss induced by ex-
enatide, and a 1.3 kg increase in skeletal muscle [37].
Semaglutide
The only study administering semaglutide reported 5.0 kg 
weight loss after 12 weeks of treatment in individuals with obe-
sity [38]. Of this weight loss, 20% was estimated, using ADP, to 
consist of LBM.
Dulaglutide
A single study of dulaglutide reported data from a case series of 
five individuals assessed before and after 12 weeks of treatment, 
using BIA [39]. This manuscript did not report total weight loss, 
but outlined 0.1 and 0.2 kg loss of LBM and skeletal muscle, re-
spectively, in comparison to 1.9 kg loss of FM.
Sodium-glucose cotransporter 2 inhibitors
We identified 27 studies examining changes in body composi-
tion with SGLT2i therapy (canagliflozin=4, dapagliflozin=6, 
empagliflozin=2, ipragliflozin=7, luseogliflozin=2, tofogli-
flozin=3, and various=3). Compared to the studies identified 
for GLP-1RAs, there was much greater use of BIA (17 studies), 
with the remaining 10 using DXA.
Canagliflozin
The most robust evidence of body composition changes with 
SGLT2i comes from a pair of randomised controlled trials 
(RCTs) reporting data on the effects of canagliflozin on DXA-
derived body composition in individuals with T2DM [40,41]. 
After 26 weeks, canagliflozin resulted in 2.5 and 3.2 kg weight 
loss at 100 and 300 mg, respectively, with the relative contribu-
tion of weight loss attributed to LBM being 36.0% and 37.5% T
ab
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Fig. 1. Relative proportions of fat mass and lean body/fat-free mass within total weight loss elicited by glucagon-like peptide-1 receptor ag-
onist therapy [25,26,28,29,31-33,35,36,38]. 
Fig. 2. Relative proportions of fat mass and lean body/fat-free mass within total weight loss elicited by sodium-glucose cotransporter 2 in-
hibitor therapy [40-46,48,50-55,57-60,62,63]. 
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[40]. At 52 weeks, the magnitude of weight loss was numerical-
ly greater than at 26 weeks and similar with both doses (–4.4 
and –4.2 kg), but the relative contribution attributed to LBM 
was lower (20.5% and 26.2%, respectively) [41]. A third study 
using DXA, resulted in 2.4 kg weight loss in individuals with 
T2DM, of which almost 46% was LBM [42]. 
A single study, using BIA to assess body composition changes 
over a longer period of time (1 year), reported the contribution of 
LBM to a total 2.9 kg weight loss in individuals with T2DM and 
NAFLD to be lower than the studies above, at just 6.9% [43].
Dapagliflozin
Two studies report changes in body composition with dapa-
gliflozin therapy using DXA, providing similar findings to those 
for canagliflozin. In a sub-study contained within a large multi-
site RCT, total weight loss after 104 weeks of dapagliflozin 
therapy in 69 participants with overweight/obesity and T2DM 
was 4.5 kg, of which 28.9% consisted of LBM [45]. A smaller, 
shorter study reported a lower magnitude of weight loss over 12 
weeks (2.1 kg) but with a similar relative contribution of LBM 
(23.8%) [45].
Three further studies, using BIA, show heterogeneous find-
ings. In a non-randomised trial in which 50 individuals with 
T2DM were prescribed dapagliflozin or non-SGLT2i therapies 
for 6 months, the dapagliflozin group lost a mean 3.4 kg of BW, 
of which 15% constituted LBM [48]. In contrast, a 12-week 
RCT reported that almost all (94%) of the 3.1 kg weight loss 
elicited with dapagliflozin was LBM [46], whilst a small cohort 
study in 11 individuals with T2DM and nonalcoholic steatohep-
atitis, reported a 1.2 kg increase in LBM after 24 weeks of treat-
ment, despite 3.8 kg weight loss [49].
Empagliflozin
Only two studies report the impact of empagliflozin on body 
composition. One of these provides DXA-derived data from a 
sub-study nested within the global EMPA-REG H2H-SU trial; a 
randomised head-to-head trial conducted as part of the empa-
gliflozin phase 3 programme, which compared empagliflozin 
with the sulphonylurea glimepiride as second line therapy 
alongside metformin in individuals with T2DM [50]. Using the 
weight loss observed in the entire population after 104 weeks 
(2.8 kg), it was estimated that approximately one-third (32.1%) 
of weight loss elicited in this trial comprised of FFM.
A separate study using BIA to assess changes with empa-
gliflozin in women with PCOS reported a loss of FFM (1.1 kg) 
which was greater than the total weight loss elicited (0.8 kg) [51].
Ipragliflozin
Of the seven studies identified for ipragliflozin, six reported that 
the contribution of LBM/FFM to total weight loss elicited 
ranged from 22% to 49% [52-55,57,59]. All of these studies 
were in individuals with T2DM, and included two studies using 
DXA, reporting 22% and 49% of 2.8 and 3.5 kg of weight loss 
over 24 weeks, respectively. The remaining four used BIA and 
in the largest and longest of these studies (n=217; 104 weeks of 
treatment), the proportion of weight loss attributed to FFM was 
approximately one-third (34.5%) [54].
In the final study identified, 24 weeks of treatment with ipra-
gliflozin resulted in a loss of FM that was greater than the total 
weight loss in individuals with T2DM and NAFLD, inferring a 
small gain (0.2 kg) in FFM [56].
Luseogliflozin
Two studies examining the effects of luseogliflozin on body 
composition using DXA report similar findings to those outlined 
above. Both studies were in individuals with T2DM, reporting 
that 12 and 52 weeks of luseogliflozin therapy elicited 2.7 and 
3.1 kg weight loss, respectively. Of this weight loss, 41% and 
32% could be attributed to a loss of FFM/LBM [59,60].
Tofogliflozin
Three similar studies, each utilising BIA, report data regarding 
the impact of tofogliflozin in individuals with T2DM. Two as-
sessed changes over 12 weeks, reporting 3.3 and 2.9 kg weight 
loss, of which 30% and 52%, respectively, could be attributed to 
LBM [62,63]. The third study reported 2.3 kg weight loss in 17 
individuals with T2DM despite an estimated 0.2 kg increase in 
FFM [61].
Various
Three cohort studies (two retrospective, one prospective) report 
data from participants prescribed SGLT2i therapy, with varia-
tion in the exact agent prescribed [64-66]. Each utilised BIA to 
assess body composition, but only one study reported changes 
in both total BW and FFM. In this study, almost half (48%) of 
the 5.2 kg weight loss elicited by dapagliflozin (n=10) or cana-
gliflozin (n=7), in individuals with overweight/obesity, T2DM 
and NAFLD, could be attributed to FFM [64].
Dual therapy of GLP-1RAs and SGLT2is in combination
We identified two studies reporting the effect of GLP-1RAs and 
SGLT2is in combination. In the first, individuals with obesity 
and pre-diabetes mellitus were randomised to dapagliflozin-
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plus-exenatide or placebo for 24 weeks, with an open-label ex-
tension (during which all participants underwent combined 
therapy) for a further 28 weeks [67]. Weight loss after 52 weeks 
was 5.7 kg, with MRI demonstrating reductions in both adipose 
tissue and lean tissue volumes (5.3 and 1.4 L, respectively). The 
second study, using BIA, reported 2.9 kg weight loss after 52 
weeks of treatment with luseogliflozin-plus-liraglutide, in indi-
viduals with T2DM, of which 14% comprised of LBM [68].
CONCLUSIONS
Our review demonstrates that, in most circumstances, the 
weight loss associated with GLP-1RA and/or SGLT2i therapy 
comprises predominantly of a reduction in FM. Within 53 
groups of individuals prescribed GLP-1RA, SGLT2i or com-
bined therapy, only five groups saw a loss of LBM, FFM, or 
skeletal muscle mass (depending on reporting) that was greater 
than FM lost. Thus, in most cases, body composition (i.e., the 
ratio of FM to FFM/LBM) was more favorable after treatment 
than before. 
However, out of 43 groups in which it was possible to esti-
mate the proportion of weight loss that could be attributed to 
LBM/FFM, in 27 groups this proportion of LBM lost ranged 
from 20% to 50%. Six groups saw a loss of LBM, FFM, or 
skeletal muscle but with a smaller relative contribution to total 
weight loss (0% to 19%), whilst another six reported an increase 
in LBM, FFM, or skeletal muscle mass. These results are in ac-
cordance with studies of diet-induced weight loss and bariatric 
surgery, which have reported similar proportions of LBM/FFM 
(approximately 25% to 40%) within total weight loss elicited 
[8,9,69-71]. 
There were no clear differences between GLP-1RAs and 
SGLT2is in the magnitude of weight loss that could be attribut-
ed to LBM/FFM. However, it should be noted that the number 
of studies identified for each class of therapy was relatively 
small, and these were divided further between multiple thera-
pies within each class. There was also heterogeneity of findings 
within each drug class and within individual therapies. Reasons 
for this heterogeneity may include (1) the specific therapy used, 
(2) the dose or duration of treatment, (3) concomitant therapies 
alongside GLP-1RA or SGLT2i treatment (e.g., if examined as 
monotherapy or dual-therapy with other glucose-lowering ther-
apies such as metformin), (4) the clinical diagnoses, background 
medication usage (i.e., use of sulphonylureas or insulin) and 
other baseline characteristics of the study population, (5) the 
technique used to assess body composition (including standardi-
sation procedures prior to measurement), and (6) natural inter-
individual variation in responses to weight loss. There are no 
clear patterns within the data collected in this review, including 
treatment type, dose or duration and the technique used.
 Although the benefits of weight loss in obesity-associated 
chronic metabolic disease are well established [72,73], these fa-
vorable outcomes may be limited by losses in LBM, particularly 
if this constitutes skeletal muscle. Of the studies identified in 
this review, 12 reported changes in either LBM or FFM, along 
with changes in skeletal muscle. In seven of these studies, the 
loss of skeletal muscle comprised between 55% and 100% of 
the LBM/FFM lost. In one it was twice as great [40], whilst an-
other reported a loss of skeletal muscle despite an increase in 
FFM [56]. The mechanism of action of SGLT2i, inducing poly-
uria alongside glycosuria, means that SGLT2i therapy is also 
associated with fluid loss [1]. Reductions in TBW may impact 
on body composition measurement, and it could be speculated 
that reductions in FFM/LBM with weight loss may reflect re-
ductions in water content. Of the 27 studies identified reporting 
changes in body composition with SGLT2i therapy, 13 reported 
changes in TBW, 12 of which reported losses; ranging from 0.2 
to 2.4 kg (7% to 100% of total weight loss). It is imperative to 
stress; however, that water is contained within both adipose- 
and non-adipose tissues [74], and all of the studies reporting 
TBW in this review utilised BIA. TBW, as provided by BIA, 
does not allow distinction between water contained in, and thus 
lost from, different body compartments (i.e., FM or FFM/
LBM). No studies reported change in TBW with GLP-1RA or 
combination therapy.
Consequently, although yielding a more favorable body com-
position, the potential LBM and skeletal muscle loss associated 
with weight loss induced by GLP-1RAs and SGLT2is warrants 
attention. A more rapid decline in skeletal muscle and conse-
quential increased risk of sarcopenia is concerning, particularly 
as individuals prescribed these therapies are usually already 
vulnerable to an increased risk of physical frailty (i.e., those 
with T2DM and/or obesity) [75]. In turn, strategies to preserve 
or increase skeletal muscle and physical function in these indi-
viduals (e.g., through structured exercise training), are of impor-
tance. It is also important to state that the absolute mass of skel-
etal muscle is not the only factor to consider, and improving 
muscular function (strength, endurance, flexibility etc.) remains 
critical to improve physical function and performance in tasks 
of daily living; to impact positively on an individual’s quality of 
life. 
Previous studies have shown that markers of physical func-
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tion (including balance, grip strength, and gait speed) improve 
following diet-induced weight loss [9,76,77], likely by reducing 
the biomechanical burden of moving around [78]. However, 
when diet and exercise are combined, improvements in physical 
function are greater than that elicited by diet alone, which may 
be underpinned by preserved or improved skeletal muscle mass 
and function [9,79]. Whether the same results are observed 
when exercise is combined with weight loss elicited by GLP-
1RAs and SGLT2i therapy is currently unknown, and requires 
testing in robust experimental research. 
Collectively, the available evidence suggests that the initiation 
of GLP-1RA or SGLT2i therapy results in weight loss that is 
primarily derived of FM. However, this is accompanied by re-
ductions in LBM which are not insignificant and should be con-
sidered in parallel to changes in FM and overall BW. Differenc-
es between therapies are currently unclear. A substantial propor-
tion of LBM loss may be comprised of skeletal muscle, which 
may be clinically relevant, particularly in the populations to 
which these therapies are prescribed. Given the heterogeneity, a 
more consistent approach to measurement and reporting of 
body composition in future research would be beneficial. As the 
prevalence of obesity, physical inactivity and associated co-
morbidities, including T2DM, continues to rise, it is imperative 
to explore strategies to preserve LBM and improve physical 
function, and particularly their interaction with glucose-lower-
ing strategies that positively impact on weight loss. 
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